Focus: Abbott is a diversified healthcare conglomerate headquartered in Abbott Park, IL, with $40.1B in FY2025 revenue spanning pharmaceuticals, diagnostics, and medical devices. It operates as a publicly traded Big Pharma company with significant device manufacturing capabilities across cardiovascular, immunology, and metabolic disease markets.
Profile data last refreshed 6h ago · AI intelligence enriched 1w ago
Hot — 3344 jobs added in 30d
Net +815 (3344 new, 2529 removed). Aggressive expansion phase.
Recent layoff filing — 53 affected
Source: state DOL filings via Big Local News
Abbott offers financial stability and scale but carries significant restructuring risk from patent cliff exposure and weak pipeline productivity—suitable for commercial/operations roles but risky for research-focused careers.
Flagship franchise representing three-quarters of company revenue; imminent patent expiration poses critical restructuring risk.
Help build intelligence for Abbott
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Abbott's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Generic antihypertensive with modest revenue; post-patent product with limited growth potential.
Niche cardiac agent with minimal revenue; approaching loss of exclusivity with negligible commercial impact.
Generic aminoglycoside antibiotic with marginal revenue; established post-patent product.
Duplicate entry for generic antihypertensive with minimal revenue footprint.
Opioid combination product in early-stage development with undisclosed indications.
Product with no disclosed indication data; approaching patent cliff with unknown commercial relevance.
Lipid emulsion product with no indication or revenue data; patent expiration imminent.
Specialty obstetric formulation with minimal commercialization data; facing patent cliff.
Anesthetic agent with no revenue or indication data; approaching loss of exclusivity.
130 discontinued, 0 duplicate formulations not shown
BSX, MDT Top Abbott Laboratories Stock on Price & Potential - Trefis
BSX, MDT Top Abbott Laboratories Stock on Price & Potential Trefis
Abbott Laboratories Stock: A Better Than 5 Years Ago—But Still Not A Buy (NYSE:ABT) - Seeking Alpha
Abbott Laboratories Stock: A Better Than 5 Years Ago—But Still Not A Buy (NYSE:ABT) Seeking Alpha
Abbott (ABT) Secures CE Mark for World’s First Dual Glucose‑Ketone Sensing Technology for Diabetes - Yahoo Finance
Abbott (ABT) Secures CE Mark for World’s First Dual Glucose‑Ketone Sensing Technology for Diabetes Yahoo Finance
Goldman Sachs Maintains Buy Rating on Abbott Laboratories (ABT) Stock - Insider Monkey
Goldman Sachs Maintains Buy Rating on Abbott Laboratories (ABT) Stock Insider Monkey
Food boxes and coaches tied to better diabetes health, less food insecurity - Stock Titan
Food boxes and coaches tied to better diabetes health, less food insecurity Stock Titan
Abbott Laboratories (ABT) Investor Outlook: Harnessing A 28.79% Potential Upside - DirectorsTalk Interviews
Abbott Laboratories (ABT) Investor Outlook: Harnessing A 28.79% Potential Upside DirectorsTalk Interviews
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent peer-reviewed publications with author affiliations at this company
Recent and ongoing layoffs indicate structural downsizing underway; further reductions highly probable as patent cliff approaches.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo